drugset / Trial / NCT00768391
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
NaSingle-groupOpen-label
Summary
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
Timeline
- Start
- 2006-12
- Primary completion
- 2009-03
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaratumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 16 mg/kg | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 20 mg/kg | Intravenous |